Fetal Diagnosis and Therapy
Fabietti I. · Vassallo C. ·
De Rose D.U. · Rapisarda A.M.C. · Romiti A. · Viggiano M. · Vicario R. · Scorletti F. · Bonito M. ·
Bagolan P. ·
Caforio L.
Log in to MyKarger to check if you already have access to this content.
Buy
FullText & PDF
Unlimited re-access via MyKarger
Unrestricted printing, no saving restrictions for personal use
read more
CHF 38.00 *
EUR 35.00 *
USD 39.00 *
Select
KAB
Buy a Karger Article Bundle (KAB) and profit from a discount!
If you would like to redeem your KAB credit, please log in.
Save over 20% compared to the individual article price.
Learn more
Access via DeepDyve
Unlimited fulltext viewing of this article
Organize, annotate And mark up articles
Printing And downloading restrictions apply
Select
Subscribe
Access to all articles of the subscribed year(s) guaranteed for 5 years
Unlimited re-access via Subscriber Login or MyKarger
Unrestricted printing, no saving restrictions for personal use
read more
Subcription rates
Select
* The final prices may differ from the prices shown due to specifics of VAT rules.
Article / Publication Details
Abstract
Introduction: Over the past years, intrafetal laser (IFL) therapy has been increasingly used in the management of various prenatal conditions. The aim of our research is to clarify the effectiveness and safety of this technique.
Methods: A systematic review of the literature was carried out using MEDLINE/PubMed over a period of 20 years (2001-2021).
Results: A total of 41 articles were selected in the literature search, including 194 cases of twin reversed arterial perfusion (TRAP) sequence, 56 cases of bronchopulmonary sequestrations (BPS), 5 cases of placental chorioangiomas (PCA), 11 cases of sacrococcygeal teratoma (SCT), and 103 cases of embryo reduction (ER) managed using IFL.
In TRAP sequence, perfusion of the acardiac twin was successfully disrupted in all cases. Preterm premature rupture of membranes (p-PROM) occurred in 6 out of 79 pregnancies (7.5%), and preterm birth (PTB) in 36 out of 122 pregnancies (29.5%). In BPS IFL was successfully performed in all cases with no significant complications. The rate of p-PROM and PTB were respectively 3.2% and 12.5%. All PCA IFL treated cases resulted in successful pregnancy outcomes; no cases of p-PROM were reported, but the rate of PTB reached a peak of 60% due to fetal complications. In SCT cases, complete cessation of blood flow was achieved in 4 patients (36.4%); p-PROM occurred in two cases (18.2%), whereas the rate of PTB was 87.5%. In ER no intraoperative or major maternal complications were described in the literature. Rates of miscarriage and PTB differed between initial trichorionic triamniotic and dichorionic triamniotic triplet pregnancies.
Discussion: Our analysis suggests that IFL is a feasible technique for the management of different fetal conditions. However, the overall risk of PTB and its related morbidity and mortality, ranges from 12.5% in BPS to 87.5% in SCT. This could aid in decision making during prenatal counselling. However final perinatal outcome depends on the severity of the disease itself.
S. Karger AG, Basel
Article / Publication Details
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
留言 (0)